These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29719240)

  • 21. Dexamethasone-tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells.
    Gaballah AI; Elsherbiny AA; Sharaky M; Hamed NO; Raslan NA; Almilaibary A; Fayyad RMA; Ousman MS; Hamdan AME; Fahim SA
    Biosci Rep; 2024 Jul; 44(7):. PubMed ID: 38864530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EZH2 inhibition sensitizes tamoxifen‑resistant breast cancer cells through cell cycle regulation.
    Chen S; Yao F; Xiao Q; Liu Q; Yang Y; Li X; Jiang G; Kuno T; Fang Y
    Mol Med Rep; 2018 Feb; 17(2):2642-2650. PubMed ID: 29207119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen promotes apoptosis and inhibits invasion in estrogen‑positive breast cancer MCF‑7 cells.
    Li W; Shi X; Xu Y; Wan J; Wei S; Zhu R
    Mol Med Rep; 2017 Jul; 16(1):478-484. PubMed ID: 28534964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells.
    Ghalehno AD; Abdi H; Boustan A; Jamialahmadi K; Mosaffa F
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3723-3732. PubMed ID: 37310508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
    Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
    Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer.
    Xie Y; Han X; Yu J; Yuan M; Yan Y; Qin J; Lan L; Wang Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18103-18117. PubMed ID: 37999751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
    Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
    Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
    Shi YF; Lu H; Wang HB
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
    BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional combination of resveratrol and tamoxifen to overcome tamoxifen-resistance in breast cancer cells.
    Radwan AM; Abosharaf HA; Sharaky M; Abdelmonem R; Effat H
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400261. PubMed ID: 38943449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Hot Melt Extruded Solid Dispersion of Tamoxifen Citrate and Resveratrol for Synergistic Effects on Breast Cancer Cells.
    Chowdhury N; Vhora I; Patel K; Bagde A; Kutlehria S; Singh M
    AAPS PharmSciTech; 2018 Oct; 19(7):3287-3297. PubMed ID: 30218267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic identification of E6AP as a molecular target of tamoxifen in MCF7 cells.
    Lochab S; Pal P; Kanaujiya JK; Tripathi SB; Kapoor I; Bhatt ML; Sanyal S; Behre G; Trivedi AK
    Proteomics; 2012 May; 12(9):1363-77. PubMed ID: 22589186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
    Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
    Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation Development of Tamoxifen Loaded Lipid Nanoparticle by Taguchi (L
    Poovi G; Damodharan N
    Curr Comput Aided Drug Des; 2021; 17(1):144-159. PubMed ID: 32196454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.
    Tiwary R; Yu W; deGraffenried LA; Sanders BG; Kline K
    Breast Cancer Res; 2011; 13(6):R120. PubMed ID: 22115051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects.
    Shete HK; Selkar N; Vanage GR; Patravale VB
    Int J Pharm; 2014 Jul; 468(1-2):1-14. PubMed ID: 24704438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.